Arcuate Therapeutics
Boston, US · Founded 2019 · Delaware corporation
Founders & leadership
AL
Andrew LevinNamed on SEC filing
JR
Joshua ResnickNamed on SEC filing
AB
Aaron BergenerNamed on SEC filing
JS
James SchneiderNamed on SEC filing
SR
Sarah ReedNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$5M disclosed across 1 round · 2019
▶$5MraisedOct 2019 · 3 investors · PharmaceuticalsRule 506(b)
▶$5MraisedOct 2019 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew LevinExecutive Officer, Director
- Joshua ResnickDirector
- Aaron BergenerExecutive Officer
- James SchneiderExecutive Officer
- Sarah ReedExecutive Officer
- Offering amount
- $10M
- Amount sold
- $5M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Arcuate Therapeutics raised?
- Arcuate Therapeutics has disclosed $5M raised across 1 round.
- Where is Arcuate Therapeutics headquartered?
- Arcuate Therapeutics is headquartered in Boston, US.